BeStock  
Stocks › Biotechnology › AKTS

Aktis Oncology AKTS

US equityMarket cap rank #3226Biotechnology
$16.15 −$0.25 (-1.52%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $16.46 +1.92%
Open$16.32
Prev close$16.40
Day range$16.00 – $16.74
Volume375.0K
Market cap$901.14M
P/E (TTM)–
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

AKTS at a glance

AKTS is priced at $16.15 right now, down 1.52% on the session. That puts its market value at $901.14M, 3226th largest among the 3753 stocks we cover.

It is close to the bottom of its 52-week range ($13.96 to $34.19), 52.8% under the high.

On the chart it has slipped under both the 50-day ($17.70) and 200-day ($20.67) moving averages; RSI is 46, and the last 30 sessions moved at roughly 63% annualized volatility.

Revenue for the quarter ended Sep 2026 was $3.91M, up 147.3% from a year earlier, and a net loss of $29.94M.

4 analysts follow the stock and the average call is "buy". The mean target, $36.50, sits 126.0% over where the stock trades.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

Key statistics

Bid / Ask$16.00 / $17.50
Average price today$16.27
Volume375.0KAvg (90d) 360.9K
Turnover$6.10M
Turnover rate1.33%of shares outstanding
Volume ratio0.88vs. recent average pace
Day amplitude4.51%
Market cap$901.14M
Float market cap$454.68M
Shares outstanding28.15M
EPS (TTM)-$1.15
P/B1.96
Book value / share$8.22
Net profit (TTM)-$64.33M
Net assets$458.88M
30-day volatility62.9%annualized
Avg daily range (ATR)5.95%of price, 14 days
Max drawdown (1y)-54.7%-49.9% from 1y peak

Quote as of Nov 20, 2026 8:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.

BeStock Grade

D
BeStock Grade

Composite of 3 factors below, ranked against the 3734 U.S. stocks BeStock covers.

F
Valuation

Cheaper than usual on its own 5-year P/E history scores higher.

F
Momentum

Trading closer to its 52-week high than most peers scores higher.

B
Wall Street

4 analysts, consensus Buy.

How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.

Six-factor research snapshot

Overall percentile: 31.1 · 2026-11-22 08:27 UTC. Higher values indicate a stronger relative ranking.

FactorPercentile
Valuation—
Growth—
Profitability1.0
Momentum12.6
Financial health97.7
Analyst view93.1

Price forecast

What Wall Street analysts and Morningstar's fair-value model expect for the stock

Analyst price target (avg)$36.50+126.0% vs. current price
Consensus ratingBuy4 analysts covering
Morningstar fair value$20.02Price is below fair value

Wall Street’s average 12-month target is $36.50, 126.0% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $20.02, so shares trade 19.3% below that estimate. On earnings multiple, it sits in the 99th percentile of its own five-year valuation range (pricier than usual).

Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
-1.5%
1 week
-2.8%
1 month
-3.6%
3 months
-37.8%
6 months
-20.6%
Day range
$16.00$16.74
52-week range
$13.96$34.19

Technical signals

Full technicals →
Trend readLeaning bearish

3 bullish · 4 bearish of 7 signals

IndicatorValueSignal
Price vs 20-day average+0.3%Bullish
Price vs 50-day average-8.7%Bearish
Price vs 200-day average-21.9%Bearish
50-day vs 200-day50d below 200dBearish
RSI (14)45.9Bearish
MACD (12,26,9)-0.35Bullish
Bollinger band position52%Bullish

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

How AKTS ranks on BeStock

Market value#3213 of 3734
Closeness to 52-week high#3116 of 3724
Dollar volume today#2625 of 3734

Ranks are among the 3,734 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.

AKTS is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.

Since 2020-12-28, the strategy has returned 401.7% (183.6% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.

Strategy Backtest

Pick a strategy above and run the backtest to see its simulated performance on AKTS.

Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.

Community Sentiment on AKTS

No votes yet — be the first to weigh in.

Reader sentiment, not investment advice. One vote per visitor; click again to change it.

AKTS stock: common questions

What is AKTS's latest share price?

$16.15 is the latest print for AKTS, a move of -1.52% against yesterday's close of $16.40. Today's low and high so far: $16.00 and $16.74.

How large is Aktis Oncology by market value?

Equity value comes to $901.14M at the current price. By that measure it is number 3226 of the 3753 names in our coverage.

Where does AKTS sit in its 52-week range?

The year's floor is $13.96 and the ceiling $34.19. Shares are 52.8% away from that ceiling.

Does AKTS send cash back through a dividend?

Our data shows no dividend paid by Aktis Oncology over the trailing twelve months.

Do Wall Street analysts like AKTS?

Of 4 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $36.50, with the most cautious at $34.00 and the most optimistic at $40.00.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Discussion

No comments yet — be the first to weigh in on AKTS.

Sign in to join the discussion.

Scroll to Top